Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Jones Day marked a strong year, climbing in both profits and head count. Mary Ellen Powers, the D.C. office’s partner in charge, says litigation, antitrust, and government regulatory matters were particularly active in 2003. “It was a terrific year for all practice groups,” says Powers. The D.C. office of the Cleveland-born mega-firm brought about 20 new lawyers on board last year. The office grossed $155.2 million, making about $50 million in profit. Profits per partner rose by 7 percent, to $945,000. Helping to boost those numbers were deals like those led by Jones Day Washington partner Vladimir Lechtman, who headed the firm’s representation of Russian oil producer TNK in its $18 billion joint venture with BP p.l.c. The largest deal in Russian corporate history, it made BP the world’s second-largest private-sector producer and the joint venture, TNK-BP, the 10th largest. British Prime Minister Tony Blair and Russian Federation President Vladimir Putin attended the signing ceremony June 26. And the D.C. office, led by Powers, garnered a win for the IBM Corp. when a California jury ruled that the computer giant was not responsible for the cancers that developed in two former employees of a disk drive plant in San Jose. The firm is one of IBM’s two chief outside counsel on the litigation, which includes more than 100 suits brought against IBM by the company’s employees, or their survivors, claiming that exposure to chemicals used by IBM between 1964 and 1996 in clean rooms caused the workers’ cancer. D.C. partner Willis Goldsmith, chair of the firm’s labor and employment practice, continued to represent Verizon Communications Inc. After its $90 billion takeover of Morris Plains, N.J.-based Warner-Lambert Co., Pfizer Inc. looked to Jones Day lawyers in the District for help with tax and restructuring issues. Jones Day Washington lawyers were also counsel for Bayer AG in antitrust litigation related to its antibiotic, Cipro. The firm is defending Bayer in 37 cases arising out of the 1997 settlement of patent litigation between Bayer and Barr Laboratories regarding Cipro. Cipro buyers allege that the settlement violated state and federal antitrust laws by restraining trade and denied plaintiffs the opportunity to purchase generic Cipro at lower prices.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.